Free Trial

OrthoPediatrics (KIDS) Financials

OrthoPediatrics logo
$22.20 +0.81 (+3.76%)
Closing price 03:59 PM Eastern
Extended Trading
$22.20 0.00 (-0.02%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for OrthoPediatrics

Annual Income Statements for OrthoPediatrics

This table shows OrthoPediatrics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
1.26 -21 -38
Consolidated Net Income / (Loss)
1.26 -21 -38
Net Income / (Loss) Continuing Operations
1.26 -21 -38
Total Pre-Tax Income
-3.69 -21 -42
Total Operating Income
-25 -27 -35
Total Gross Profit
91 111 149
Total Revenue
122 149 205
Operating Revenue
122 149 205
Total Cost of Revenue
32 37 56
Operating Cost of Revenue
32 37 56
Total Operating Expenses
116 138 184
Selling, General & Admin Expense
58 73 103
Marketing Expense
46 53 64
Research & Development Expense
8.45 11 11
Impairment Charge
3.61 0.99 1.84
Restructuring Charge
0.00 0.00 3.65
Total Other Income / (Expense), net
22 5.44 -6.92
Interest Expense
2.42 -0.20 5.85
Other Income / (Expense), net
24 5.24 -1.07
Income Tax Expense
-4.95 -0.34 -4.11
Basic Earnings per Share
$0.06 ($0.92) ($1.64)
Weighted Average Basic Shares Outstanding
20.70M 22.68M 23.08M
Diluted Earnings per Share
$0.06 ($0.92) ($1.64)
Weighted Average Diluted Shares Outstanding
20.95M 22.68M 23.08M
Weighted Average Basic & Diluted Shares Outstanding
22.99M 23.55M 24.29M

Quarterly Income Statements for OrthoPediatrics

This table shows OrthoPediatrics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
19 -7.85 -6.81 -2.89 -4.59 -6.69 -7.81 -6.03 -7.92 -16
Consolidated Net Income / (Loss)
19 -7.85 -6.81 -2.89 -4.59 -6.69 -7.81 -6.03 -7.92 -16
Net Income / (Loss) Continuing Operations
19 -7.85 -6.81 -2.89 -4.59 -6.69 -7.81 -6.03 -7.92 -16
Total Pre-Tax Income
14 -7.90 -7.38 -3.29 -3.74 -6.90 -10 -6.05 -9.14 -16
Total Operating Income
-6.96 -8.31 -8.59 -5.59 -4.51 -8.07 -9.72 -5.67 -5.57 -14
Total Gross Profit
26 21 24 30 31 27 32 41 40 36
Total Revenue
35 31 32 40 40 38 45 53 55 53
Operating Revenue
35 31 32 40 40 38 45 53 55 53
Total Cost of Revenue
9.06 9.77 8.03 9.53 9.02 11 13 12 15 17
Operating Cost of Revenue
9.06 9.77 8.03 9.53 9.02 11 13 12 15 17
Total Operating Expenses
33 30 32 36 35 35 42 46 46 50
Selling, General & Admin Expense
15 15 17 19 18 19 25 27 26 24
Marketing Expense
12 12 13 14 14 13 14 17 17 17
Research & Development Expense
2.21 2.47 2.45 2.97 2.56 2.92 3.00 2.54 2.58 2.92
Total Other Income / (Expense), net
21 0.41 1.21 2.30 0.77 1.16 -0.61 -0.38 -3.57 -2.35
Interest Expense
0.71 -0.06 -0.21 0.29 0.02 -0.30 0.64 0.26 3.63 1.32
Other Income / (Expense), net
22 -2.22 1.00 2.59 0.79 0.86 0.02 -0.12 0.06 -1.04
Income Tax Expense
-4.14 -0.05 -0.57 -0.40 0.85 -0.21 -2.53 -0.02 -1.22 -0.34
Basic Earnings per Share
$0.88 ($0.33) ($0.30) ($0.13) ($0.20) ($0.29) ($0.34) ($0.26) ($0.34) ($0.70)
Weighted Average Basic Shares Outstanding
21.15M 20.70M 22.51M 22.70M 22.76M 22.68M 22.82M 23.15M 23.17M 23.08M
Diluted Earnings per Share
$0.87 ($0.32) ($0.30) ($0.13) ($0.20) ($0.29) ($0.34) ($0.26) ($0.34) ($0.70)
Weighted Average Diluted Shares Outstanding
21.30M 20.95M 22.51M 22.70M 22.76M 22.68M 22.82M 23.15M 23.17M 23.08M
Weighted Average Basic & Diluted Shares Outstanding
22.89M 22.99M 23.33M 23.35M 23.35M 23.55M 23.83M 24.21M 24.22M 24.29M

Annual Cash Flow Statements for OrthoPediatrics

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
1.46 23 13
Net Cash From Operating Activities
-22 -27 -27
Net Cash From Continuing Operating Activities
-22 -27 -27
Net Income / (Loss) Continuing Operations
1.26 -21 -38
Consolidated Net Income / (Loss)
1.26 -21 -38
Depreciation Expense
13 17 19
Non-Cash Adjustments To Reconcile Net Income
13 13 19
Changes in Operating Assets and Liabilities, net
-49 -36 -28
Net Cash From Investing Activities
-113 42 -13
Net Cash From Continuing Investing Activities
-113 42 -13
Purchase of Property, Plant & Equipment
-10 -17 -14
Acquisitions
-40 -3.10 -23
Purchase of Investments
-110 -51 -26
Sale and/or Maturity of Investments
47 113 50
Net Cash From Financing Activities
136 7.30 53
Net Cash From Continuing Financing Activities
136 7.30 53
Repayment of Debt
-31 -0.14 -16
Issuance of Debt
31 9.42 74
Issuance of Common Equity
139 0.00 0.00
Other Financing Activities, net
-3.17 -1.98 -4.61
Effect of Exchange Rate Changes
0.62 0.63 -0.18
Cash Interest Paid
0.70 0.04 2.75

Quarterly Cash Flow Statements for OrthoPediatrics

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents
-1.28 -26 26 -25 0.92 21 -9.46 7.33 22 -7.12
Net Cash From Operating Activities
-6.06 -3.34 -6.46 -4.37 -8.67 -7.54 -6.69 -6.09 -10 -3.99
Net Cash From Continuing Operating Activities
-6.06 -3.34 -6.46 -4.37 -8.67 -7.54 -6.69 -6.09 -10 -3.99
Net Income / (Loss) Continuing Operations
19 -7.85 -6.81 -2.89 -4.59 -6.69 -7.81 -6.03 -7.92 -16
Consolidated Net Income / (Loss)
19 -7.85 -6.81 -2.89 -4.59 -6.69 -7.81 -6.03 -7.92 -16
Depreciation Expense
3.29 3.52 3.85 4.08 4.27 5.19 5.03 4.78 5.28 3.99
Non-Cash Adjustments To Reconcile Net Income
5.67 2.08 2.49 3.73 3.63 3.03 3.08 3.20 7.21 5.88
Changes in Operating Assets and Liabilities, net
-34 -1.10 -6.00 -9.30 -12 -9.07 -6.99 -8.04 -15 2.21
Net Cash From Investing Activities
-104 -23 32 -18 9.67 18 -3.68 20 -27 -2.41
Net Cash From Continuing Investing Activities
-104 -23 32 -18 9.67 18 -3.68 20 -27 -2.41
Purchase of Property, Plant & Equipment
-1.09 0.52 -4.94 -5.62 -3.03 -3.84 -6.46 -6.68 -1.38 0.26
Acquisitions
-32 - 0.00 -48 -4.00 49 -21 - -25 23
Purchase of Investments
-85 -25 - - - - - - - -25
Net Cash From Financing Activities
108 -0.04 -0.04 -2.04 -0.02 9.39 -0.57 -4.27 59 -0.54
Net Cash From Continuing Financing Activities
108 -0.04 -0.04 -2.04 -0.02 9.39 -0.57 -4.27 59 -0.54
Repayment of Debt
-31 -0.04 -0.04 -0.04 -0.04 -0.04 -0.57 -0.77 -15 0.57
Other Financing Activities, net
0.02 - - - 0.02 - - - - -1.11
Cash Interest Paid
0.45 0.19 0.01 - 0.02 0.01 0.22 0.54 0.62 1.37

Annual Balance Sheets for OrthoPediatrics

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets
428 439 473
Total Current Assets
227 226 237
Cash & Equivalents
8.99 31 44
Restricted Cash
1.47 1.97 1.96
Short-Term Investments
109 49 25
Accounts Receivable
25 35 42
Inventories, net
78 106 117
Prepaid Expenses
3.97 3.75 7.02
Plant, Property, & Equipment, net
34 41 51
Total Noncurrent Assets
167 171 185
Goodwill
87 84 94
Intangible Assets
80 85 81
Other Noncurrent Operating Assets
0.00 2.94 10
Total Liabilities & Shareholders' Equity
428 439 473
Total Liabilities
49 62 119
Total Current Liabilities
31 42 34
Short-Term Debt
0.14 0.15 0.16
Accounts Payable
11 13 8.91
Current Employee Benefit Liabilities
6.74 11 14
Other Current Liabilities
13 18 11
Total Noncurrent Liabilities
18 20 85
Long-Term Debt
0.76 9.91 73
Noncurrent Deferred & Payable Income Tax Liabilities
5.95 5.48 3.38
Other Noncurrent Operating Liabilities
11 4.66 8.34
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
379 377 355
Total Preferred & Common Equity
379 377 355
Total Common Equity
379 377 355
Common Stock
561 580 601
Retained Earnings
-177 -198 -236
Accumulated Other Comprehensive Income / (Loss)
-5.40 -5.53 -11

Quarterly Balance Sheets for OrthoPediatrics

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets
430 426 435 432 437 431 489
Total Current Assets
225 225 223 226 204 194 248
Cash & Equivalents
35 35 9.71 11 22 29 51
Restricted Cash
1.45 1.48 1.60 1.59 1.96 1.96 2.00
Short-Term Investments
85 73 83 72 26 0.00 25
Accounts Receivable
26 27 34 38 36 42 43
Inventories, net
74 85 91 101 113 116 121
Prepaid Expenses
2.75 4.01 3.64 3.98 5.06 4.50 6.49
Plant, Property, & Equipment, net
36 37 40 40 49 53 55
Total Noncurrent Assets
169 164 172 166 185 183 186
Goodwill
88 84 83 81 91 91 91
Intangible Assets
81 80 88 85 89 87 85
Other Noncurrent Operating Assets
- - 0.61 0.62 4.08 6.47 10
Total Liabilities & Shareholders' Equity
430 426 435 432 437 431 489
Total Liabilities
47 53 55 58 67 59 118
Total Current Liabilities
29 35 44 48 46 40 35
Short-Term Debt
0.14 0.15 0.15 0.15 0.15 0.16 0.16
Accounts Payable
11 17 21 23 20 17 12
Current Employee Benefit Liabilities
6.32 6.24 8.16 8.67 9.77 13 13
Other Current Liabilities
11 12 15 17 16 9.80 9.60
Total Noncurrent Liabilities
18 18 10 10 21 20 84
Long-Term Debt
0.80 0.73 0.69 0.65 10 9.78 73
Noncurrent Deferred & Payable Income Tax Liabilities
5.46 6.02 5.56 5.49 5.20 4.74 4.03
Other Noncurrent Operating Liabilities
12 11 4.00 4.05 5.43 5.38 7.21
Total Equity & Noncontrolling Interests
383 373 380 374 371 371 371
Total Preferred & Common Equity
383 373 380 374 371 371 371
Total Common Equity
383 373 380 374 371 371 371
Common Stock
559 563 575 578 583 593 597
Retained Earnings
-169 -184 -186 -191 -206 -212 -219
Accumulated Other Comprehensive Income / (Loss)
-7.10 -6.05 -7.91 -12 -6.96 -10 -6.60

Annual Metrics and Ratios for OrthoPediatrics

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - -
Revenue Growth
24.72% 21.62% 37.65%
EBITDA Growth
365.28% -134.86% -312.07%
EBIT Growth
91.65% -1,600.40% -67.73%
NOPAT Growth
-40.92% -5.32% -30.87%
Net Income Growth
107.74% -1,767.25% -80.33%
EPS Growth
107.14% -1,633.33% -78.26%
Operating Cash Flow Growth
-66.62% -24.26% -0.01%
Free Cash Flow Firm Growth
-217.08% 39.91% -20.17%
Invested Capital Growth
51.48% 17.33% 17.09%
Revenue Q/Q Growth
5.32% 4.66% 7.94%
EBITDA Q/Q Growth
-38.24% 54.74% -114.62%
EBIT Q/Q Growth
-118.68% 13.38% -27.96%
NOPAT Q/Q Growth
65.44% 0.90% -20.64%
Net Income Q/Q Growth
-86.29% 5.23% -32.97%
EPS Q/Q Growth
-84.21% 3.16% -33.33%
Operating Cash Flow Q/Q Growth
-10.71% -18.39% 11.62%
Free Cash Flow Firm Q/Q Growth
29.75% -34.69% 19.14%
Invested Capital Q/Q Growth
-1.10% 4.70% -2.36%
Profitability Metrics
- - -
Gross Margin
74.14% 74.80% 72.58%
EBITDA Margin
9.68% -2.77% -8.30%
Operating Margin
-20.77% -17.99% -17.10%
EBIT Margin
-1.03% -14.46% -17.62%
Profit (Net Income) Margin
1.03% -14.10% -18.47%
Tax Burden Percent
-34.10% 98.41% 90.20%
Interest Burden Percent
291.62% 99.08% 116.22%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-8.24% -6.63% -7.41%
ROIC Less NNEP Spread (ROIC-NNEP)
-30.29% -4.28% 30.69%
Return on Net Nonoperating Assets (RNNOA)
8.66% 1.08% -2.93%
Return on Equity (ROE)
0.42% -5.55% -10.34%
Cash Return on Invested Capital (CROIC)
-49.19% -22.58% -23.15%
Operating Return on Assets (OROA)
-0.35% -4.97% -7.91%
Return on Assets (ROA)
0.34% -4.84% -8.29%
Return on Common Equity (ROCE)
0.42% -5.55% -10.34%
Return on Equity Simple (ROE_SIMPLE)
0.33% -5.56% -10.67%
Net Operating Profit after Tax (NOPAT)
-18 -19 -25
NOPAT Margin
-14.54% -12.59% -11.97%
Net Nonoperating Expense Percent (NNEP)
22.04% -2.35% -38.10%
Return On Investment Capital (ROIC_SIMPLE)
-4.68% -4.84% -5.73%
Cost of Revenue to Revenue
25.86% 25.20% 27.42%
SG&A Expenses to Revenue
47.35% 49.28% 50.21%
R&D to Revenue
6.91% 7.33% 5.39%
Operating Expenses to Revenue
94.91% 92.79% 89.68%
Earnings before Interest and Taxes (EBIT)
-1.27 -22 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
12 -4.13 -17
Valuation Ratios
- - -
Price to Book Value (P/BV)
2.40 2.01 1.58
Price to Tangible Book Value (P/TBV)
4.29 3.64 3.13
Price to Revenue (P/Rev)
7.44 5.10 2.74
Price to Earnings (P/E)
722.96 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.14% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
3.04 2.25 1.58
Enterprise Value to Revenue (EV/Rev)
6.47 4.62 2.75
Enterprise Value to EBITDA (EV/EBITDA)
66.81 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.03 0.21
Long-Term Debt to Equity
0.00 0.03 0.21
Financial Leverage
-0.29 -0.25 -0.10
Leverage Ratio
1.21 1.15 1.25
Compound Leverage Factor
3.53 1.14 1.45
Debt to Total Capital
0.24% 2.60% 17.10%
Short-Term Debt to Total Capital
0.04% 0.04% 0.04%
Long-Term Debt to Total Capital
0.20% 2.56% 17.06%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
99.76% 97.40% 82.90%
Debt to EBITDA
0.08 -2.44 -4.30
Net Debt to EBITDA
-10.04 17.51 -0.14
Long-Term Debt to EBITDA
0.06 -2.40 -4.29
Debt to NOPAT
-0.05 -0.54 -2.98
Net Debt to NOPAT
6.69 3.86 -0.09
Long-Term Debt to NOPAT
-0.04 -0.53 -2.98
Altman Z-Score
11.37 7.43 2.84
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
7.34 5.44 6.98
Quick Ratio
4.64 2.76 3.27
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-106 -64 -77
Operating Cash Flow to CapEx
-216.99% -155.22% -189.64%
Free Cash Flow to Firm to Interest Expense
-43.76 0.00 -13.09
Operating Cash Flow to Interest Expense
-8.98 0.00 -4.62
Operating Cash Flow Less CapEx to Interest Expense
-13.12 0.00 -7.06
Efficiency Ratios
- - -
Asset Turnover
0.33 0.34 0.45
Accounts Receivable Turnover
5.72 5.01 5.32
Inventory Turnover
0.47 0.41 0.50
Fixed Asset Turnover
3.89 3.95 4.47
Accounts Payable Turnover
3.09 3.15 5.21
Days Sales Outstanding (DSO)
63.79 72.91 68.62
Days Inventory Outstanding (DIO)
783.34 896.18 724.60
Days Payable Outstanding (DPO)
118.14 115.89 70.09
Cash Conversion Cycle (CCC)
728.99 853.20 723.13
Capital & Investment Metrics
- - -
Invested Capital
260 305 357
Invested Capital Turnover
0.57 0.53 0.62
Increase / (Decrease) in Invested Capital
88 45 52
Enterprise Value (EV)
791 687 564
Market Capitalization
909 759 561
Book Value per Share
$16.54 $16.14 $14.64
Tangible Book Value per Share
$9.26 $8.94 $7.41
Total Capital
380 387 428
Total Debt
0.91 10 73
Total Long-Term Debt
0.76 9.91 73
Net Debt
-119 -72 2.33
Capital Expenditures (CapEx)
10 17 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)
76 103 133
Debt-free Net Working Capital (DFNWC)
196 185 203
Net Working Capital (NWC)
196 185 203
Net Nonoperating Expense (NNE)
-19 2.25 13
Net Nonoperating Obligations (NNO)
-119 -72 2.33
Total Depreciation and Amortization (D&A)
13 17 19
Debt-free, Cash-free Net Working Capital to Revenue
62.34% 69.05% 64.76%
Debt-free Net Working Capital to Revenue
160.27% 124.37% 99.34%
Net Working Capital to Revenue
160.15% 124.27% 99.26%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.06 ($0.92) ($1.64)
Adjusted Weighted Average Basic Shares Outstanding
20.70M 22.68M 23.08M
Adjusted Diluted Earnings per Share
$0.06 ($0.92) ($1.64)
Adjusted Weighted Average Diluted Shares Outstanding
20.95M 22.68M 23.08M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
22.99M 23.55M 24.29M
Normalized Net Operating Profit after Tax (NOPAT)
-15 -18 -21
Normalized NOPAT Margin
-12.47% -12.13% -10.09%
Pre Tax Income Margin
-3.02% -14.33% -20.48%
Debt Service Ratios
- - -
EBIT to Interest Expense
-0.52 0.00 -6.17
NOPAT to Interest Expense
-7.33 0.00 -4.19
EBIT Less CapEx to Interest Expense
-4.66 0.00 -8.60
NOPAT Less CapEx to Interest Expense
-11.47 0.00 -6.63
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for OrthoPediatrics

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
39.36% 24.91% 34.89% 20.14% 14.37% 21.36% 41.46% 33.48% 36.53% 40.02%
EBITDA Growth
2,912.08% -2,290.00% -12.71% -71.17% -97.01% 71.19% -24.83% -192.64% -140.62% -449.63%
EBIT Growth
547.26% -322.81% -20.84% -780.23% -124.64% 31.55% -27.79% -93.32% -47.89% -109.41%
NOPAT Growth
-251.43% -49.42% -34.53% -49.24% 64.80% 2.92% -13.18% -1.43% -23.47% -74.25%
Net Income Growth
943.83% -11,000.00% 25.21% -766.67% -124.76% 14.74% -14.68% -108.91% -72.49% -140.16%
EPS Growth
890.91% 0.00% 36.17% -550.00% -122.99% 9.38% -13.33% -100.00% -70.00% -141.38%
Operating Cash Flow Growth
-546.53% -170.53% -53.94% 46.47% -43.10% -125.77% -3.54% -39.31% -18.57% 47.14%
Free Cash Flow Firm Growth
-633.48% -280.57% -250.61% -55.37% 70.89% 46.17% 27.67% 18.73% -147.95% -22.24%
Invested Capital Growth
61.02% 51.48% 56.08% 38.56% 10.82% 17.33% 25.06% 22.34% 25.56% 17.09%
Revenue Q/Q Growth
6.14% -11.32% 1.92% 25.23% 1.04% -5.90% 18.80% 18.16% 3.35% -3.49%
EBITDA Q/Q Growth
387.70% -138.11% 46.60% 129.05% -49.49% -467.76% -131.35% 78.44% 77.86% -4,876.23%
EBIT Q/Q Growth
3,332.73% -169.70% 27.91% 60.57% -24.32% -93.66% -34.60% 40.34% 4.89% -174.21%
NOPAT Q/Q Growth
-242.14% 35.12% -3.39% 34.98% 19.30% -78.93% -20.54% 41.73% 1.76% -152.52%
Net Income Q/Q Growth
5,667.27% -142.33% 13.28% 57.60% -59.08% -45.74% -16.65% 22.75% -31.35% -102.92%
EPS Q/Q Growth
4,450.00% -136.78% 6.25% 56.67% -53.85% -45.00% -17.24% 23.53% -30.77% -105.88%
Operating Cash Flow Q/Q Growth
25.85% 44.85% -93.39% 32.32% -98.24% 12.99% 11.31% 8.94% -68.73% 61.21%
Free Cash Flow Firm Q/Q Growth
-101.66% 13.27% -7.50% 17.36% 62.22% -60.40% -44.45% 7.15% -15.26% 20.92%
Invested Capital Q/Q Growth
27.10% -1.10% 1.93% 8.14% 1.66% 4.70% 8.65% 5.78% 4.34% -2.36%
Profitability Metrics
- - - - - - - - - -
Gross Margin
74.07% 68.48% 74.59% 75.90% 77.44% 71.02% 72.00% 77.27% 73.41% 67.53%
EBITDA Margin
52.62% -22.61% -11.85% 2.75% 1.37% -5.37% -10.45% -1.91% -0.41% -21.07%
Operating Margin
-19.92% -26.81% -27.20% -14.12% -11.28% -21.44% -21.76% -10.73% -10.20% -26.69%
EBIT Margin
43.22% -33.97% -24.03% -7.57% -9.31% -19.16% -21.71% -10.96% -10.08% -28.65%
Profit (Net Income) Margin
53.04% -25.32% -21.55% -7.30% -11.49% -17.79% -17.47% -11.42% -14.51% -30.51%
Tax Burden Percent
128.78% 99.39% 92.22% 87.80% 122.69% 96.93% 75.51% 99.70% 86.67% 97.93%
Interest Burden Percent
95.31% 75.00% 97.23% 109.82% 100.56% 95.80% 106.57% 104.51% 166.04% 108.74%
Effective Tax Rate
-28.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-13.99% -10.64% -11.43% -5.50% -4.05% -7.91% -8.27% -4.13% -4.12% -11.56%
ROIC Less NNEP Spread (ROIC-NNEP)
-44.78% -8.29% -10.40% -7.29% -2.64% -6.82% -6.92% -0.54% 4.96% 6.27%
Return on Net Nonoperating Assets (RNNOA)
13.23% 2.37% 2.72% 1.37% 0.71% 1.72% 1.37% 0.08% -0.59% -0.60%
Return on Equity (ROE)
-0.75% -8.27% -8.71% -4.12% -3.34% -6.19% -6.90% -4.05% -4.71% -12.16%
Cash Return on Invested Capital (CROIC)
-70.92% -49.19% -52.69% -40.69% -17.09% -22.58% -28.82% -26.24% -28.85% -23.15%
Operating Return on Assets (OROA)
13.68% -11.35% -8.62% -2.71% -3.07% -6.58% -8.14% -4.43% -4.15% -12.86%
Return on Assets (ROA)
16.79% -8.46% -7.73% -2.61% -3.78% -6.11% -6.55% -4.62% -5.97% -13.70%
Return on Common Equity (ROCE)
-0.75% -8.27% -8.71% -4.12% -3.34% -6.19% -6.90% -4.05% -4.71% -12.16%
Return on Equity Simple (ROE_SIMPLE)
2.39% 0.00% 0.95% 0.26% -5.91% 0.00% -5.93% -6.76% -7.67% 0.00%
Net Operating Profit after Tax (NOPAT)
-8.96 -5.82 -6.01 -3.91 -3.16 -5.65 -6.81 -3.97 -3.90 -9.84
NOPAT Margin
-25.65% -18.77% -19.04% -9.88% -7.89% -15.01% -15.23% -7.51% -7.14% -18.68%
Net Nonoperating Expense Percent (NNEP)
30.80% -2.35% -1.03% 1.79% -1.41% -1.09% -1.35% -3.59% -9.08% -17.83%
Return On Investment Capital (ROIC_SIMPLE)
- -1.53% - - - -1.46% - - - -2.30%
Cost of Revenue to Revenue
25.93% 31.52% 25.41% 24.10% 22.56% 28.98% 28.00% 22.73% 26.59% 32.47%
SG&A Expenses to Revenue
43.25% 48.64% 54.31% 48.31% 44.96% 50.67% 55.34% 51.76% 48.19% 46.39%
R&D to Revenue
6.31% 7.98% 7.74% 7.50% 6.41% 7.77% 6.71% 4.82% 4.72% 5.54%
Operating Expenses to Revenue
93.99% 95.29% 101.79% 90.02% 88.71% 92.47% 93.76% 88.00% 83.61% 94.21%
Earnings before Interest and Taxes (EBIT)
15 -11 -7.59 -2.99 -3.72 -7.21 -9.70 -5.79 -5.50 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
18 -7.01 -3.74 1.09 0.55 -2.02 -4.67 -1.01 -0.22 -11
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.44 2.40 2.73 2.69 2.00 2.01 1.85 1.85 1.77 1.58
Price to Tangible Book Value (P/TBV)
4.37 4.29 4.88 4.89 3.58 3.64 3.62 3.53 3.37 3.13
Price to Revenue (P/Rev)
8.06 7.44 7.81 7.46 5.26 5.10 4.24 3.91 3.46 2.74
Price to Earnings (P/E)
101.94 722.96 286.71 1,023.92 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.98% 0.14% 0.35% 0.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
3.10 3.04 3.44 3.24 2.28 2.25 1.95 1.90 1.78 1.58
Enterprise Value to Revenue (EV/Rev)
7.02 6.47 6.98 6.78 4.67 4.62 4.00 3.79 3.43 2.75
Enterprise Value to EBITDA (EV/EBITDA)
42.53 66.81 79.74 106.43 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
120.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.03 0.20 0.21
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.03 0.20 0.21
Financial Leverage
-0.30 -0.29 -0.26 -0.19 -0.27 -0.25 -0.20 -0.15 -0.12 -0.10
Leverage Ratio
1.21 1.21 1.24 1.26 1.14 1.15 1.16 1.15 1.24 1.25
Compound Leverage Factor
1.16 0.91 1.20 1.38 1.14 1.10 1.24 1.20 2.05 1.36
Debt to Total Capital
0.25% 0.24% 0.23% 0.22% 0.21% 2.60% 2.71% 2.61% 16.38% 17.10%
Short-Term Debt to Total Capital
0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
Long-Term Debt to Total Capital
0.21% 0.20% 0.19% 0.18% 0.17% 2.56% 2.67% 2.57% 16.35% 17.06%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.75% 99.76% 99.77% 99.78% 99.79% 97.40% 97.29% 97.39% 83.62% 82.90%
Debt to EBITDA
0.05 0.08 0.08 0.10 -0.09 -2.44 -2.04 -1.39 -9.18 -4.30
Net Debt to EBITDA
-6.30 -10.04 -9.49 -10.76 9.13 17.51 7.80 2.93 0.68 -0.14
Long-Term Debt to EBITDA
0.04 0.06 0.06 0.08 -0.07 -2.40 -2.01 -1.37 -9.16 -4.29
Debt to NOPAT
-0.02 -0.05 -0.05 -0.04 -0.04 -0.54 -0.53 -0.51 -3.58 -2.98
Net Debt to NOPAT
2.35 6.69 5.61 4.56 4.40 3.86 2.02 1.07 0.27 -0.09
Long-Term Debt to NOPAT
-0.02 -0.04 -0.04 -0.03 -0.03 -0.53 -0.52 -0.50 -3.57 -2.98
Altman Z-Score
12.40 11.29 11.68 11.44 7.89 7.54 6.26 7.02 3.57 2.98
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
7.81 7.34 6.39 5.04 4.72 5.44 4.45 4.90 7.17 6.98
Quick Ratio
5.09 4.64 3.82 2.87 2.51 2.76 1.83 1.79 3.43 3.27
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-109 -94 -101 -84 -32 -51 -73 -68 -78 -62
Operating Cash Flow to CapEx
-556.29% 0.00% -130.79% -77.77% -286.58% -196.64% -103.56% -91.14% -744.32% 0.00%
Free Cash Flow to Firm to Interest Expense
-153.26 0.00 0.00 -284.36 -1,503.93 0.00 -114.87 -260.31 -21.55 -46.95
Operating Cash Flow to Interest Expense
-8.56 0.00 0.00 -14.87 -412.81 0.00 -10.50 -23.34 -2.83 -3.02
Operating Cash Flow Less CapEx to Interest Expense
-10.09 0.00 0.00 -34.00 -556.86 0.00 -20.64 -48.95 -3.21 -2.82
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.32 0.33 0.36 0.36 0.33 0.34 0.37 0.40 0.41 0.45
Accounts Receivable Turnover
5.24 5.72 5.83 4.63 4.45 5.01 5.13 4.61 4.71 5.32
Inventory Turnover
0.44 0.47 0.47 0.46 0.42 0.41 0.42 0.43 0.45 0.50
Fixed Asset Turnover
3.57 3.89 3.84 3.58 3.71 3.95 3.78 3.74 3.99 4.47
Accounts Payable Turnover
2.88 3.09 2.23 2.05 2.17 3.15 2.30 2.35 2.92 5.21
Days Sales Outstanding (DSO)
69.68 63.79 62.60 78.92 81.97 72.91 71.17 79.10 77.43 68.62
Days Inventory Outstanding (DIO)
826.61 783.34 781.28 794.69 876.47 896.18 859.42 851.67 809.55 724.60
Days Payable Outstanding (DPO)
126.72 118.14 163.96 177.93 168.03 115.89 158.43 155.64 125.14 70.09
Cash Conversion Cycle (CCC)
769.56 728.99 679.91 695.67 790.41 853.20 772.17 775.12 761.84 723.13
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
263 260 265 286 291 305 331 350 366 357
Invested Capital Turnover
0.55 0.57 0.60 0.56 0.51 0.53 0.54 0.55 0.58 0.62
Increase / (Decrease) in Invested Capital
100 88 95 80 28 45 66 64 74 52
Enterprise Value (EV)
815 791 910 929 664 687 647 664 651 564
Market Capitalization
936 909 1,018 1,023 747 759 687 685 656 561
Book Value per Share
$18.90 $16.54 $16.23 $16.30 $16.03 $16.14 $15.74 $15.58 $15.32 $14.64
Tangible Book Value per Share
$10.56 $9.26 $9.08 $8.98 $8.95 $8.94 $8.07 $8.15 $8.05 $7.41
Total Capital
384 380 374 381 375 387 381 381 444 428
Total Debt
0.94 0.91 0.87 0.84 0.80 10 10 9.94 73 73
Total Long-Term Debt
0.80 0.76 0.73 0.69 0.65 9.91 10 9.78 73 73
Net Debt
-121 -119 -108 -94 -83 -72 -39 -21 -5.39 2.33
Capital Expenditures (CapEx)
1.09 -0.52 4.94 5.62 3.03 3.84 6.46 6.68 1.38 -0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)
74 76 81 84 94 103 108 123 136 133
Debt-free Net Working Capital (DFNWC)
196 196 190 179 178 185 158 154 214 203
Net Working Capital (NWC)
196 196 190 179 178 185 158 154 214 203
Net Nonoperating Expense (NNE)
-28 2.03 0.79 -1.02 1.44 1.04 1.00 2.06 4.02 6.23
Net Nonoperating Obligations (NNO)
-121 -119 -108 -94 -83 -72 -39 -21 -5.39 2.33
Total Depreciation and Amortization (D&A)
3.29 3.52 3.85 4.08 4.27 5.19 5.03 4.78 5.28 3.99
Debt-free, Cash-free Net Working Capital to Revenue
64.06% 62.34% 61.85% 61.50% 66.41% 69.05% 66.96% 70.53% 71.59% 64.76%
Debt-free Net Working Capital to Revenue
168.77% 160.27% 145.56% 130.64% 125.53% 124.37% 97.67% 88.18% 112.74% 99.34%
Net Working Capital to Revenue
168.65% 160.15% 145.45% 130.53% 125.42% 124.27% 97.58% 88.09% 112.66% 99.26%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.88 ($0.33) ($0.30) ($0.13) ($0.20) ($0.29) ($0.34) ($0.26) ($0.34) ($0.70)
Adjusted Weighted Average Basic Shares Outstanding
21.15M 20.70M 22.51M 22.70M 22.76M 22.68M 22.82M 23.15M 23.17M 23.08M
Adjusted Diluted Earnings per Share
$0.87 ($0.32) ($0.30) ($0.13) ($0.20) ($0.29) ($0.34) ($0.26) ($0.34) ($0.70)
Adjusted Weighted Average Diluted Shares Outstanding
21.30M 20.95M 22.51M 22.70M 22.76M 22.68M 22.82M 23.15M 23.17M 23.08M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
22.89M 22.99M 23.33M 23.35M 23.35M 23.55M 23.83M 24.21M 24.22M 24.29M
Normalized Net Operating Profit after Tax (NOPAT)
-2.35 -5.82 -6.01 -3.91 -2.47 -5.65 -6.81 -3.97 -3.90 -9.84
Normalized NOPAT Margin
-6.71% -18.77% -19.04% -9.88% -6.17% -15.01% -15.23% -7.51% -7.14% -18.68%
Pre Tax Income Margin
41.19% -25.48% -23.36% -8.31% -9.36% -18.35% -23.13% -11.45% -16.74% -31.16%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
21.33 0.00 0.00 -10.18 -177.19 0.00 -15.23 -22.17 -1.51 -11.44
NOPAT to Interest Expense
-12.66 0.00 0.00 -13.30 -150.27 0.00 -10.68 -15.20 -1.07 -7.46
EBIT Less CapEx to Interest Expense
19.80 0.00 0.00 -29.31 -321.24 0.00 -25.37 -47.78 -1.89 -11.24
NOPAT Less CapEx to Interest Expense
-14.20 0.00 0.00 -32.43 -294.31 0.00 -20.83 -40.81 -1.45 -7.26
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About OrthoPediatrics' Financials

When does OrthoPediatrics's financial year end?

According to the most recent income statement we have on file, OrthoPediatrics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has OrthoPediatrics' net income changed over the last 2 years?

OrthoPediatrics' net income appears to be on an upward trend, with a most recent value of -$37.82 million in 2024, falling from $1.26 million in 2022. The previous period was -$20.97 million in 2023. Find out what analysts predict for OrthoPediatrics in the coming months.

What is OrthoPediatrics's operating income?
OrthoPediatrics's total operating income in 2024 was -$35.01 million, based on the following breakdown:
  • Total Gross Profit: $148.60 million
  • Total Operating Expenses: $183.61 million
How has OrthoPediatrics revenue changed over the last 2 years?

Over the last 2 years, OrthoPediatrics' total revenue changed from $122.29 million in 2022 to $204.73 million in 2024, a change of 67.4%.

How much debt does OrthoPediatrics have?

OrthoPediatrics' total liabilities were at $118.64 million at the end of 2024, a 92.2% increase from 2023, and a 141.7% increase since 2022.

How much cash does OrthoPediatrics have?

In the past 2 years, OrthoPediatrics' cash and equivalents has ranged from $8.99 million in 2022 to $43.82 million in 2024, and is currently $43.82 million as of their latest financial filing in 2024.

How has OrthoPediatrics' book value per share changed over the last 2 years?

Over the last 2 years, OrthoPediatrics' book value per share changed from 16.54 in 2022 to 14.64 in 2024, a change of -11.5%.



This page (NASDAQ:KIDS) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners